Spots Global Cancer Trial Database for Myeloproliferative Neoplasms and Bone Structure

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Myeloproliferative Neoplasms and Bone Structure

Official Title: Myeloproliferative Neoplasms and Bone Structure

Study ID: NCT01816022

Conditions

Polycythemia Vera

Thrombocythemia, Essential

Primary Myelofibrosis

Interventions

Study Description

Brief Summary: This is a clinical study to evaluate the effect of CMPN (Chronic myeloproliferative neoplasm) to the bone. The hypothesis is that patients with CMPN have a higher fracture-rate compared to the background population. We expect to find a lower BMD using conventional DXA scan (dual energy x-ray absorptiometry), and a change in other parameters using HR-pQCT (high-resolution peripheral quantitative computerized tomography).Biochemical bone markers is measured to support the hypothesis.

Detailed Description: This is a clinical study to evaluate the effect of CMPN to the bone. Three individual cohorts are defined; a cohort consisting of 50 patients with Polycythemia Vera (PV), a cohort consisting of 50 patients with Essential Thrombocythemia (ET), and a cohort consisting of 25 patients with Primary Myelofibrosis (PMF). Patients are recruited from the Department of Hematology, Odense University Hospital. Interventions consist of: * Conventional DXA scan to measure Bone Mineral Density (BMD). * Experimental HR-pQCT to assess geometry, strength and microstructure of the bone in 3 dimension. * Blood-samples are collected and frozen for later analyses of Biochemical Bone Markers: 1-CTP, Ctx, ALP (alkaline phosphatase)and P1NP. The outcome is compared to healthy control individuals.